Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBIP-1435
- Development stage
- Unknown
- Lead developer
- Neurocrine Biosciences
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
NBIP-1435 is a long-acting synthetic peptide antagonist of the corticotropin-releasing factor type 1 receptor (CRHR1 or CRF1) developed primarily for the treatment of congenital adrenal hyperplasia (CAH), a rare genetic disorder affecting adrenal steroid hormone production[1][2][3][4][5][6][7][8][9][10]. It is Neurocrine Biosciences’ first investigational biologic candidate to enter clinical trials and is administered as a subcutaneous injection. CRF1 antagonism by NBIP-1435 is designed to normalize adrenal androgen levels and may reduce the required dose of glucocorticoids, potentially addressing significant side effects of standard CAH therapy[2][5][9]. The compound originated from a proprietary peptide research collaboration between Neurocrine Biosciences and Sentia Medical Sciences, with Neurocrine holding exclusive development and commercialization rights[2][3][5].
- Brand names
- NBIP-01435NBIP01435NBIP 01435
- Other names
- NBIP-01435NBIP01435NBIP 01435NBIP-1435NBIP1435NBIP 1435
02
Targets
CRHR1 (Corticotropin-releasing factor receptor 1)
Beyond the preview
Go deeper on NBIP-1435.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBIP-1435.